In Brief: LabCorp settlement:
This article was originally published in The Gray Sheet
LabCorp settlement: Laboratory Corporation of America agrees to pay $187 mil. to the U.S. government to settle allegations of billing improprieties by its predecessor companies, National Health Laboratories, Roche Biomedical Laboratories and Allied Clinical Laboratories. The labs, which merged to form LabCorp in 1995, have been under federal investigation since 1993 for allegedly billing unnecessary tests as part of chemistry profiles. The settlement includes a $5 mil. payment to settle criminal charges against a San Diego lab sold by Allied in 1992 but indemnified by LabCorp, as well as a $182 mil. payment to settle civil claims involving Medicare and related government billings...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.